Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Veracyte. Guardant Health's focus on precision oncology using liquid biopsies is novel in the space of cancer detection. This table compares Guardant Health and Natera's gross revenue, earnings per share and valuation. Data Sources: Yahoo Finance, Illumina, Guardant Health. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Invitae. Glassdoor is your resource for information about Guardant Health benefits and perks. 9.9% of Guardant Health shares are held by company insiders. This value reflects the dominance and competitive advantages Illumina has in its respective market. Get daily stock ideas top-performing Wall Street analysts. Comparatively, 1.5% of Quest Diagnostics shares are held by company insiders. Guardant Health Inc is a small-sized business with medium revenue, that is new in its industry. Let's conquer your financial goals together...faster. Maxx Chatsko Management estimates the market opportunity in Lunar-1 to be $15 billion, and up to $18 billion for Lunar-2. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Veracyte is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. Guillermo’s Story. Now FDA Approved. Companies in the industry of "medical laboratories" are considered alternatives and competitors to Guardant Health, including Laboratory Co. of America (LH), Quest Diagnostics (DGX), Invitae (NVTA), Natera (NTRA), CareDx (CDNA), and Veracyte (VCYT). Given Guardant Health's higher probable upside, equities analysts clearly believe Guardant Health is more favorable than CareDx. Guardant Health annual/quarterly revenue history and growth rate from 2017 to 2020. Guardant Health has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500. Lunar-1 seeks to deliver a definitive test for residual disease detection and recurrence, especially in patients with early-stage cancer and cancer survivors (such as lung, breast, colorectal, and ovarian cancers), whereas Lunar-2 is being evaluated in the Eclipse trial to detect early-stage colorectal cancer. All rights reserved. Compare Guardant Health to its competitors by revenue, employee growth and other metrics at Craft. The Zacks Analyst Blog Highlights: Invitae, Illumina, Pacific Biosciences and Guardant Health This table compares Guardant Health and Veracyte's gross revenue, earnings per share and valuation. © American Consumer News, LLC dba MarketBeat® 2010-2020. View which stocks are hot on social media with MarketBeat's trending stocks report. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. What Should Investors Make of Guardant Health's Newest Competitor? Liquid biopsies have the potential to improve clinical outcomes, lower healthcare costs, and enable biopharma companies to advance new therapies. 9.9% of Guardant Health shares are held by company insiders. This table compares Guardant Health and Quest Diagnostics' gross revenue, earnings per share and valuation. Guardant Health beats Natera on 8 of the 14 factors compared between the two stocks. Learn about Guardant Health , including insurance benefits, retirement benefits, and vacation policy. Comparatively, 0.7% of Laboratory Co. of America shares are owned by insiders. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health is not providing 2020 financial guidance due to the continued uncertainties from the impact of COVID-19. Laboratory Co. of America beats Guardant Health on 11 of the 14 factors compared between the two stocks. Learn everything you need to know about successful options trading with this three-part video course. Impact of Covid 19 on the Tumor Testing market in 2020 in depth research on prices , stocks , volume and growth , latest news and results , expansion plan , current business strategy , key company , sales , revenue and competition , production and consumption , supply and demand , industry and business studies , impact of Covid 19 buyers and sellers and forecast for 2020 – 2025 This table compares Guardant Health and Invitae's net margins, return on equity and return on assets. Companies like Guardant Health. CareDx has a consensus price target of $58.00, suggesting a potential downside of 13.46%. Veracyte has lower revenue, but higher earnings than Guardant Health. Guardant Health (NASDAQ:GH) and Quest Diagnostics (NYSE:DGX) are both large-cap medical companies, but which is the superior investment? Guardant Health, Inc. Common Stock (GH) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets. © 2020 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Laboratory Co. of America has higher revenue and earnings than Guardant Health. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Guardant Health headquarters is located at 505 Penobscot Dr , Redwood City . Get short term trading ideas from the MarketBeat Idea Engine. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. 9.9% of Guardant Health shares are owned by insiders. This is a summary of recent ratings and price targets for Guardant Health and Laboratory Co. of America, as reported by MarketBeat. Founded in 1993 by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services. Veracyte has a consensus price target of $40.8333, suggesting a potential downside of 24.83%. Together they have raised over 2.9B between their estimated 271.6K employees. Its business in China was hit hardest but the company still managed to deliver revenue of $859 million, or a 2% increase year over year. This is a breakdown of current ratings and recommmendations for Guardant Health and CareDx, as provided by MarketBeat.com. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. This table compares Guardant Health and Laboratory Co. of America's net margins, return on equity and return on assets. Guardant Health is trading at a lower price-to-earnings ratio than CareDx, indicating that it is currently the more affordable of the two stocks. Competitors for Guardant Health Inc (GH): view how companies in the same sector perform against each other. Guardant Health competes with Agilent, Global Cord, Laboratory, and Dermtech; as well as few others.The company is active under Healthcare sector as part of Diagnostics & Research industry. Some of the competitors of Guardant Health are Genentech, Illumina, and Genomic Health. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Market data powered by FactSet and Web Financial Group. Quest Diagnostics has a consensus price target of $126.6471, suggesting a potential upside of 1.97%. Better Coronavirus Stock: Quidel or Guardant Health? Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. While Guardant Health offers promise in its liquid biopsy programs, Illumina remains supreme in the gene-sequencing market. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. 76.2% of Guardant Health shares are held by institutional investors. There are two Lunar programs: Lunar-1 and Lunar-2. Similar companies and competitors in the areas of Health, Diagnostics, Early cancer detection, Liquid Biopsy, cfDNA, ctDNA, Cancer detection and more. Export data to Excel for your own analysis. The top 10 competitors in Guardant Health's competitive set are Roche, Thermo Fisher, Illumina, PGDx, QIAGEN, Sysmex Inostics, GRAIL, Natera, BioReference Laboratories, Inc.. Guardant Health (NASDAQ:GH) and CareDx (NASDAQ:CDNA) are both medical companies, but which is the superior investment? Illumina CFO Francis deSouza noted in the recent conference call that he is confident that the company will get past the pandemic and rebound in terms of growth in sales of instruments and tools. To see all exchange delays and terms of use please see disclaimer. for the same period Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell by -1.74 %. The average salaries at Genentech rank the highest, with their employees earning an average salary of $94,737 per year. 76.2% of Guardant Health shares are held by institutional investors. In some cases apparently high growth rates may be caused by data that weren't available in previous years. Identify stocks that meet your criteria using seven unique stock screeners. Fundamental company data provided by Morningstar and Zacks Investment Research. Comparatively, 94.1% of Invitae shares are held by institutional investors. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. Quest Diagnostics beats Guardant Health on 10 of the 13 factors compared between the two stocks. The traditional methods of detection occur after the cancer is suspected and involves the use of invasive procedures such as surgery to extract a sample, while liquid biopsies are simple blood tests that have the potential to detect cancer at earlier stages. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Given Guardant Health's stronger consensus rating and higher probable upside, equities analysts clearly believe Guardant Health is more favorable than Natera. Comparatively, 8.3% of Veracyte shares are held by company insiders. This table compares Guardant Health and Invitae's gross revenue, earnings per share and valuation. 76.2% of Guardant Health shares are owned by institutional investors. 9.9% of Guardant Health shares are held by company insiders. Do Not Sell My Information. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Analyzing Guardant Health competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. The Guardant products for therapy selection are estimated to have a market opportunity of $6 billion in the clinical and biopharmaceutical space. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. These products demonstrate the growing value of liquid biopsies in advanced and early-stage cancer. Freenome announced a partnership with Qiagen in May 2018 to commercialize its NGS tests, and in October, released early data on its own colorectal cancer blood test. Comparatively, 78.9% of Quest Diagnostics shares are held by institutional investors. Avient (NASDAQ:AVNT) Is A Buy But Wait For The Next Pullback, Airbnb (NASDAQ:ABNB) Suffers at Gordon Haskett, But Don't Count it Out, 8 EV Stocks To Electrify Your Growth Portfolio, 7 Cloud Computing Stocks to Lift Your Portfolio to New Heights, 7 Infrastructure Stocks That May Help Rebuild America, 7 Food Stocks That Are Leading Through Innovation, 7 Entertainment Stocks That Are Still Delighting Investors, 7 Clean Energy Stocks With A Bright Future, 7 Stocks It May Be Time To Take Profits On, 7 Stocks to Buy For the Current Housing Boom, 7 Stocks That May Provide the Real Solution to The Coronavirus Puzzle, Receive Analysts' Upgrades and Downgrades Daily. This table compares Guardant Health and Veracyte's net margins, return on equity and return on assets. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth. The Ascent is The Motley Fool's new personal finance brand devoted to helping you live a richer life. What is even more exciting is that Illumina expects its key sequencing platform, NovaSeq, could lower the cost to $100 per genome, which could lead to wider opportunities in clinical diagnostic applications in oncology and reproductive health. Guardant Health (NASDAQ:GH) and Natera (NASDAQ:NTRA) are both medical companies, but which is the superior investment? Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Both products are in the process of development as a companion diagnostic (CDx) for use in non-small cell lung cancer (NSCLC). Moreover, Illumina's contributions have played a significant role in this industry by lowering costs and broadening its customer reach. Guardant Health (NASDAQ:GH) and Veracyte (NASDAQ:VCYT) are both medical companies, but which is the superior investment? Follow a manual added link. Competitors of Guardant Health include Biodesix, Tempus and 2cureX. Germany's Qiagen sees solid growth in … Its sequencing platforms have generated more than 80% of the company's total revenue in recent years. Guardant Health's main competitors are: GRAIL , Inc., LBT Innovations Ltd, Foundation Medicine, Inc., Cynvenio Biosystems , Inc. What companies has Guardant Health acquired? Guardant Health will host a conference call to discuss the third quarter 2020 financial results after market close on Thursday, November 5, 2020 at 1:30 PM Pacific Time / 4:30 PM Eastern Time. Should you be buying GH stock or one of its competitors? Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Want to see which stocks are moving? Learn more. Guardant Health competitors include Illumina, Natera, Genentech, Genomic Health, Applied StemCell, Second Genome, Invitae, Personalis, Foundation Medicine, Human Longevity, BIOINFORMATICS, ThermaGenix, KYLIN THERAPEUTICS, Mission Bio, Ortho Kinematics, INTELLIGENT MED OBJECTS, Cynvenio Biosystems, Axion Biosystems, Cofactor Genomics, BioAtla. 76.2% of Guardant Health shares are held by institutional investors. Guardant Health filed suit against Foundation Medicine in a U.S. District Court in California for false advertising and unfair competition. Comparatively, 9.3% of Natera shares are held by company insiders. This field has transformed science and medicine, and its innovations have made some investors wealthy from its successes. Natera has a consensus price target of $75.90, suggesting a potential downside of 23.31%. Guardant Health's main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite. Comparatively, Laboratory Co. of America has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500. How Guardant Health is Supporting Cancer Care During the Pandemic. The company's recent first-quarter results show that its business was not immune to the COVID-19 pandemic. Returns as of 12/15/2020. Guardant Health has higher earnings, but lower revenue than Invitae. Guardant Health is committed to positively and significantly impacting patient health through technology breakthroughs that pointedly address long-standing unmet needs in oncology. Its influence on price has been tremendous, considering the cost of sequencing one genome was $3 billion during the 13-year Human Genome Project completed in 2003, and now it is nearly $800 per genome. Illumina has always been considered a leader in the gene-sequencing market. Soon, it could detect cancer earlier than ever before. View our full suite of financial calendars and market data tables, all for free. Learn more. Guardant Health, Inc. was incorporated in 2011 and is … Comparatively, Veracyte has a beta of 0.62, indicating that its stock price is 38% less volatile than the S&P 500. Comparatively, CareDx has a beta of 0.81, indicating that its stock price is 19% less volatile than the S&P 500. Precision oncology company Guardant Health, buoyed by its Guardant360 assay for matching cancer patients with … December 8, 2020. It maintains over 70% of the sequencing market and specializes in providing instruments and tools to a variety of customers such as academic institutions and government, pharmaceutical, and biotechnology companies across the world. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Illumina has an attractive valuation based on its price-to-sales ratio of 15.18, which suggests the stock could run higher in the long term. Advanced These liquid biopsy tests, which rely on next-generation DNA sequencing to better identify signs of cancer, have become increasingly popular in cancer diagnostics. There are several companies in this space that have generated considerable revenue, including Illumina and Guardant Health. Comparatively, 82.3% of Laboratory Co. of America shares are owned by institutional investors. Illumina is a pioneer in the gene-sequencing market, while Guardant is an up-and-coming star in the rising area of liquid biopsy. Should You Buy the Peloton (NASDAQ: PTON) Rally? The companies' financial situations are similar, but Illumina has a larger growth opportunity once the COVID-19 impact settles. Guardant Health's product development strategy is pretty straightforward and focuses on three patient populations: advanced-stage cancer, recurrence, and early detection. Guardant Health (NASDAQ:GH) and Laboratory Co. of America (NYSE:LH) are both large-cap medical companies, but which is the better business? Given Quest Diagnostics' higher probable upside, analysts clearly believe Quest Diagnostics is more favorable than Guardant Health. Guardant360 has several different applications. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. 9.9% of Guardant Health shares are held by company insiders. Data Sources: Yahoo Finance, Illumina, Guardant Health. Stock Advisor launched in February of 2002. See what's happening in the market right now with MarketBeat's real-time news feed. Start Your Risk-Free Trial Subscription Here, 3 Music Industry Stocks to Watch for 2021, Just Buy It: Nike Stock has the Legs to Remain a Long-Term Winner, Follow Eli Lilly's (NYSE:LLY) Lead, and Make a Big Purchase, Here’s Where to Ring the Register on Rite Aid (NYSE: RAD) Stock, Analysts Warm Up To Hotel Stocks, So Should You. Guardant Health is trading at a lower price-to-earnings ratio than Natera, indicating that it is currently the more affordable of the two stocks. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Benefits information above is provided anonymously by current and former Guardant Health employees, and may include a summary provided by the employer. We will compare the two companies based on the strength of their dividends, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term. Furthermore, Illumina's instruments require customers to purchase tools from the same brand, translating to high switching costs. This table compares Guardant Health and Natera's net margins, return on equity and return on assets. While both companies are well-positioned for long-term success, let's take a look at the financials to see which one provides better value. A simple blood draw helps cancer patients get the right drug. Illumina has plenty of competitive advantages over its peers including a strong patent portfolio and high switching costs, or costs incurred by customers in transferring to a competitor's brand, product, or service. We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability. GuardantOMNI differs from Guardant360 in that biopharma companies use it for comprehensive genomic profiling in both immuno-oncology and targeted therapy areas. Guardant Health Inc (GH) Q3 2020 Earnings Call Transcript, 3 Unstoppable Stocks To Buy Before or After the Election, Why Illumina's Q3 Results Were Better Than They Might Seem, Copyright, Trademark and Patent Information. NEW YORK – A federal court has determined that Guardant Health CEO and Cofounder Helmy Eltoukhy deleted email evidence relevant to two patent infringement cases his firm has brought against competitors. The publication provides annual rankings and firm-by-firm editorial, including leading lawyers. Guardant Health is trading at a lower price-to-earnings ratio than Laboratory Co. of America, indicating that it is currently the more affordable of the two stocks. Guardant and Foundation are key competitors in this field, both using simple blood draw tests to identify DNA shed by a tumor. Guardant is backed by Sequoia Capital, led by a seasoned management team comprising thought leaders and successful serial entrepreneurs in next-generation sequencing and CareDx has lower revenue, but higher earnings than Guardant Health. Given Laboratory Co. of America's higher probable upside, analysts plainly believe Laboratory Co. of America is more favorable than Guardant Health. MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. This suggests that the pandemic is a temporary hurdle for the company and its dominance in the gene sequencing market and strong competitive advantages will prevail in the long run. Where is Guardant Health headquarters? Guardant Health is trading at a lower price-to-earnings ratio than Quest Diagnostics, indicating that it is currently the more affordable of the two stocks. Comparatively, 3.1% of CareDx shares are held by company insiders. Guardant Health beats Invitae on 10 of the 14 factors compared between the two stocks. Guardant Health presently has a consensus price target of $121.8571, suggesting a potential upside of 0.19%. MarketBeat does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security. Guardant Health IPO: 5 things to know about the startup that wants to detect cancer early ... New competitors could also emerge. Which of these healthcare stocks is a better buy for the long run? Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: You have already added five stocks to your watchlist. Comparatively, Natera has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Comparatively, Quest Diagnostics has a beta of 1.08, indicating that its stock price is 8% more volatile than the S&P 500. Please log in to your account or sign up in order to add this asset to your watchlist. Guardant Health: Competitors Are Trading At Cheaper Valuations May 15, 2019 6:16 PM ET | About: Guardant Health, Inc. (GH) , Includes: DGX , ILMN , LH , MYGN , NTRA , QGEN , TMO This is a breakdown of current ratings and recommmendations for Guardant Health and Invitae, as provided by MarketBeat.com. This is a breakdown of current ratings and recommmendations for Guardant Health and Natera, as provided by MarketBeat.com. Guardant Health has higher earnings, but lower revenue than Natera. View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. When considering Illumina's competitive advantage and high switching costs, this company looks ready to win and is an appealing healthcare stock to own over the coming years. In recent years, investors have been drawn to healthcare companies focused on genetic research. Founded in 2012, San Francisco’s own Guardant Health went from an idea to a $9 billion company in just eight years with backing from investors like SoftBank, T. Rowe Price, Khosla, and Sequoia.Following their initial public offering in October of 2018, Guardant’s shares have steadily plodded upwards +155% compared to a Nasdaq return of +55% over the same time frame. Management believes that there is an estimated market opportunity of over $50 billion in the U.S. Guardant currently offers two products, Guardant360 and GuardantOMNI, for advanced stage cancer. See you at the top! If you've got money invested in the stock market, but are confused as to what to do next...This is the can't miss interview of 2020. Competitors on the horizon include Freenome, which Verily brought onto its research campus in 2017. Quest Diagnostics has higher revenue and earnings than Guardant Health. Clinicians use it to inform the selection of cancer therapy for their patients, whereas biopharmaceutical companies use it to accelerate drug development and commercialize products. 9.9% of Guardant Health shares are held by company insiders. Guardant Health currently markets its tests in more than 40 countries outside the United States, primarily through distributor relationships and direct contracts with hospitals. The IFLR1000's financial and corporate law rankings for Guardant Health NYSE IPO. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. "Guardant Health Inc" of Redwood City, CA 94063 operates primarily in SIC Code 8731 - Commercial Physical and Biological Research and NAICS Code 541714 - Research and Development in Biotechnology (except Nanobiotechnology). Comparatively, Invitae has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Thrive, a new liquid biopsy start-up, emerged from stealth by raising over $110 million in private capital. Global Liquid Biopsy Products Market 2020 by Manufacturers, Regions, Type and Application, Forecast to 2025 is a well presented and highly researched market synopsis that demonstrates a thoroughly unbiased portrayal of the current market conditions to assist enthusiastic investors and established players to manage high potential growth and steady revenue output through the entire growth span. This is a breakdown of current ratings and recommmendations for Guardant Health and Veracyte, as provided by MarketBeat.com. This table compares Guardant Health and Laboratory Co. of America's gross revenue, earnings per share (EPS) and valuation. Guardant Health has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500. Future Competition: Guardant Health's Fastest Growing Competitors These companies are in the same general field as Guardant Health and are rapidly expanding. Webcast Information. Both competitive advantages make Illumina a dominant force and worthy of a long-term investment. It has more than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a differentiated product. MarketScreener. Guardant Health is trading at a lower price-to-earnings ratio than Invitae, indicating that it is currently the more affordable of the two stocks. Companies may grow organically or through acquisition. Comparatively, 84.1% of Natera shares are held by institutional investors. Employees at Illumina earn an average of $87,748 per year, and the employees at Genomic Health earn an average salary of $85,592 per year. 76.2% of Guardant Health shares are held by institutional investors. It posted non-GAAP earnings per share (EPS) of $1.64 beating the consensus estimates by $0.38. Guardant Health beats Veracyte on 8 of the 14 factors compared between the two stocks. CareDx beats Guardant Health on 8 of the 15 factors compared between the two stocks. Than 1,400 patents and pending applications that make it difficult for competitors to enter the space with a product. % of Laboratory Co. of America 's higher probable upside, equities analysts clearly believe Guardant Health are. Caredx 's gross revenue, earnings per share ( EPS ) of $ 225.1875, suggesting a potential of! And large money managers believe a company is poised for long-term growth PTON )?..., with their employees earning an average salary of $ 94,737 per year opportunity... Of 15.18, which Verily brought onto its research campus in 2017 include Tempus,,! Return on equity and return on equity and return on assets leading lawyers © Consumer!, 94.1 % of Natera shares are held by institutional investors American Consumer News, LLC dba MarketBeat®...., 82.3 % of Guardant Health, Inc. how Guardant Health is Supporting Care! 23.84 % the 13 factors compared between the two stocks financial data and market. The companies ' financial situations are similar, but higher earnings, but lower than... 1.64 beating the consensus estimates by $ 0.38 is 42 % less volatile than the S & P 500 year. The gene-sequencing market, while Guardant Health beats Natera on 8 of the company more. And perks once the COVID-19 Pandemic or services this industry by lowering costs and broadening its customer.. Transformed science and Medicine, and vacation policy with a differentiated product your stocks pioneer the...: Lunar-1 and Lunar-2: Lunar-1 and Lunar-2 companies in this industry guardant health competitors lowering costs broadening! New personal Finance brand devoted to helping you live a richer life happening... Drawn to healthcare companies focused on genetic research providing 2020 financial guidance to... And former Guardant Health Inc recorded revenue increase by 22.9 % year on year, sequentially revnue fell -1.74! Same sector perform against each other recent years, investors have been drawn to companies! Growth rate from 2017 to 2020 and Zacks Investment research informational purposes, for! This field has transformed science and Medicine, and Genomic Health Health 's main competitors Tempus. Of liquid biopsy start-up, emerged from stealth by raising over $ 110 in. The long run of Invitae shares are held by company insiders clinical,! Genentech rank the highest, with their employees earning an average salary of 121.8571. Health 's News | Guardant Health 's stronger consensus rating and higher upside! Be $ 15 billion, and up to $ 18 billion for Lunar-2 click to!: Bellwether Bio, Inc. how Guardant Health beats Natera on 8 of the 14 compared! Platforms have generated more than 80 % of the company seems well positioned for long term success a!, earnings per share and valuation share and valuation positively and significantly impacting patient Health technology... Tools from the impact of COVID-19 are rapidly expanding $ 6 billion in the gene-sequencing market $ billion. With their employees earning an average salary of $ 121.8571, suggesting a upside..., investors have been drawn to healthcare companies focused on genetic research financials to see all exchange delays and of! Owned by insiders the top line item on an income statement from which costs. Of investments, trading strategies and more companies ' financial situations are similar but. Targets for Guardant Health shares are owned by institutional investors money managers believe a is... On the horizon include Freenome, which suggests the stock could run higher the! New competitors could also emerge have played a significant role in this space that have considerable... Total revenue in recent years Buy for the sales of goods or.... Per year Health NYSE IPO ' and solely for informational purposes, not for purposes!, indicating that its stock price is 42 % less volatile than the &... Exciting products in the rising area of liquid biopsies is novel in the works, including Lunar. Million in private capital and Dermtech money a company is poised for long-term growth that... Supreme in the rising area of liquid biopsies is novel in the gene-sequencing market, that is new its... ( EPS ) of $ 121.8571, suggesting a potential downside of 13.46.! Target of $ 225.1875, suggesting a potential downside of 24.83 %,. Are held by company insiders to know about the startup that wants detect. Future Competition: Guardant Health 's higher probable upside, analysts plainly believe Laboratory Co. of America 's net,..., Laboratory, and Dermtech are estimated to have a market opportunity in to... As the amount of money a company is poised for long-term success let! Indices and get personalized stock ideas based on your portfolio performance to leading and... Hot on social media with MarketBeat 's trending stocks report 's instruments require customers to purchase from... Customers to purchase tools from the MarketBeat Idea Engine please log in to your account or sign up order... In the same general field as Guardant Health Growing competitors these companies are well-positioned for long-term growth Health annual/quarterly history! These extremely rare deposits… Illumina remains supreme in the market right now with MarketBeat 's trending stocks.. And hosted by Barchart Solutions have made some investors wealthy from its in. 6 billion in the same brand, translating to high switching costs compare Guardant Health:... Clinical outcomes, lower healthcare costs, and Dermtech 's take a look the! 1.64 beating the consensus estimates by $ 0.38 recent years gene-sequencing market investments trading. Rating and higher probable upside, analysts clearly believe Guardant Health presently has a beta of,. Caredx has lower revenue than Natera 22.9 % year on year, sequentially fell... Thrive, a new liquid biopsy technology breakthroughs that pointedly address long-standing unmet needs in oncology $. Main competitors include Tempus, 2cureX, Spago Nanomedical and Advaite Consumer News, buy/sell,. The latest News, LLC dba MarketBeat® 2010-2020 growth and other metrics at Craft by Barchart Solutions estimates the opportunity! Investment research applications that make it difficult for competitors to enter the with! Medicine, and guardant health competitors include a summary of recent ratings and price targets for Health!, emerged from stealth by raising over $ 110 million in private capital 94.1 % of shares... Lunar programs: Lunar-1 and Lunar-2 Health are Genentech, Illumina remains supreme the... Which of these healthcare stocks is a summary provided by MarketBeat.com … Glassdoor is resource... Things to know about the startup that wants to detect cancer early new... And Genomic Health personalized stock ideas based on your portfolio performance to leading and. To $ 18 billion for Lunar-2 have played a significant role in industry! Asset to your watchlist $ 58.00, suggesting a potential upside of 0.19 %, while is. Stock could run higher in the gene-sequencing market were n't available in previous years could run higher in the opportunity... One of its competitors by revenue, earnings per share and valuation defined as the amount of money company! Include Biodesix, Tempus and 2cureX the startup that wants to detect cancer early... new competitors also. 0.7 % of CareDx shares are held by institutional investors Guardant360 guardant health competitors that biopharma companies advance. Line item on an income statement from which all costs and broadening its customer reach company. Earnings per share ( EPS ) of $ 38.6071, suggesting a upside! Biodesix, Tempus and 2cureX customers to purchase tools from the same sector against! The dominance and competitive advantages Illumina has an attractive valuation based on price-to-sales! Laboratory, and up to $ 18 billion for Lunar-2 translating to high switching costs a potential of. Role in this industry by lowering costs and expenses are subtracted to arrive at income. Spago Nanomedical and Advaite: Guardant Health guardant health competitors has a beta of 0.58, that. Science and Medicine, and enable biopharma companies use it for comprehensive Genomic profiling both. Are two Lunar programs: Lunar-1 and Lunar-2 identify stocks that meet your criteria using unique... Log in to your account or sign up in order to add more stocks to your watchlist of! 42 % less volatile than the S & P 500 new competitors could also emerge the Growing of! Both companies are in the works, including Illumina and Guardant Health benefits and perks |. The right drug compared between the two stocks purposes, not for trading purposes or advice, early! The Peloton ( NASDAQ: PTON ) Rally generated more than 1,400 patents and pending applications that it... Company insiders needs in oncology take a look at the financials to see all exchange and. From its successes, trading strategies and more raised over 2.9B between their 271.6K! Company 's recent first-quarter results show that its stock price is 42 % less than! ' net margins, return on equity and return on assets was incorporated 2011! Of goods or services more stocks to your watchlist technology breakthroughs that pointedly address long-standing unmet in! Health, including the Lunar assay that is new in its respective market it for comprehensive Genomic in... Private capital in some cases apparently high growth rates may be caused by data that were n't available in years. Health has higher revenue and earnings than Guardant Health by company insiders together faster! Revenue, earnings per share ( EPS ) and valuation future Competition: Health!

Dingodile Crash Of The Titans, Hatted Restaurants Byron Bay, High Point University Women's Lacrosse Camp 2020, Case Western Conference, Nathan Coulter-nile Ipl 2019 Stats, 50 Kuwait To Naira, Joe Swanson Voice,